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A b s t r a c t
Background: Lactate is an end-product of anaerobic cell metabolism. Although it is believed to have prognostic significance 
in heart failure (HF), data on the pathomechanisms that lead to lactate accumulation are scarce. 
Aim: We aimed to determine the clinical, respiratory, biochemical, and haemodynamic correlates of lactate in HF.
Methods: Patients diagnosed with HF hospitalised in a single cardiac centre, who underwent haemodynamic monitoring, 
were included in this retrospective analysis.
Results: The population consisted of 93 patients (44 acute HF [AHF] and 49 chronic HF [CHF] cases). The mean age, left 
ventricular ejection fraction, and lactate level were 60 ± 13 years, 33% ± 17%, 1.4 ± 0.9 mmol/L, respectively. The mean 
cardiac index (CI), right atrial pressure (RAP) and pulmonary capillary wedge pressure (PCWP) were 2.2 ± 0.5 L/min/m2, 
8.7 ± 6 mmHg, and 18 ± 6 mmHg, respectively. AHF patients had significantly higher RAP, heart rate (HR), and levels of 
N-terminal pro–B-type natriuretic peptide and creatinine, compared to the CHF group. Both HR and natriuretic peptide level 
were correlated with lactate. Among haemodynamic indices, lactate correlated with CI (r = –0.25, p = 0.01). We found no 
correlation between lactate and RAP (p > 0.05) or PCWP (p > 0.05). There was no relationship between lactate and peripheral 
blood gases. Lactate was strongly correlated with mixed venous oxygen saturation (svO2) (r = –0.61, p < 0.05). HR, svO2, 
and systemic vascular resistance (SVR) were found to be independent determinants of lactate. 
Conclusions: Lactate accumulation in HF is not a result of respiratory disturbances or hypoxaemia. Among haemodynamic 
indices, CI is correlated with lactate. The strongest determinants of lactate included svO2, SVR, and HR.
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INTRODUCTION
Lactate is an end-product of anaerobic cell metabolism, 
which occurs during tissue hypoxia; therefore, it is a useful 
laboratory biomarker reflecting the severity of this phenom-
enon [1]. To date, lactate has been extensively studied in 
critical care medicine, and it is a well-established marker of 
poor outcome [2–4]. Data on the clinical significance and 
pathophysiology of lactate in heart failure (HF) remain scarce 
[5–7]. Recently, we demonstrated that elevated lactate level 
is common in acute HF patients (even without overt, clinical 
signs of hypoperfusion) and is related to organ dysfunction 
and higher mortality [7]. 
However, the exact mechanisms leading to hyperlac-
tataemia in HF are still poorly explored. There are several 
potential pathways leading to accumulation of lactates in 
a failing heart: (i) insufficient supply of blood and oxygen 
to the peripheral tissues due to hypoxaemia leading to hy-
poxia, low cardiac output, vasoconstriction, impaired tissue 
perfusion (as a consequence of congestion and elevation 
of central venous pressure), or inability of the tissues to 
increase oxygen extraction; (ii) higher oxygen demand due 
to adrenergic drive and neurohormonal activation; and 
(iii) impaired lactate clearance — inability to eliminate the 
produced lactate.
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For better understanding of the pathophysiology of hyper-
lactataemia in HF, we attempted to investigate the respiratory, 
biochemical, and haemodynamic determinants of lactate in 
HF patients who underwent haemodynamic monitoring. 
METHODS
Study population
We conducted a retrospective analysis of patients who were 
hospitalised in the Centre of Heart Diseases, 4th Military Hos-
pital, Wroclaw, Poland between March 2008 and December 
2012 due to a primary diagnosis of HF, and who underwent 
haemodynamic monitoring with a Swan-Ganz catheter.
Exclusion criteria for the analysis were clinical and labora-
tory signs of infection, septic shock, known liver disease, and 
a diagnosis of acute coronary syndrome on admission. For 
the purpose of the present study, only patients with available 
lactate during catheterisation were included. Thus, 93 out of 
158 patients who underwent haemodynamic monitoring in 
our institution composed the final study group. All patients 
underwent standard clinical evaluation and transthoracic 
echocardiography with the assessment of left ventricular 
ejection fraction (LVEF, Simpson’s method) and end-diastolic 
dimensions of the left and right ventricles. 
Patients were treated in accordance with the recom-
mendations of the European Society of Cardiology [8]. The 
study protocol was approved by the local Ethics Committee 
(approvals number 282/2010 and 387/2015), and the study 
was conducted in accordance with the Helsinki Declaration.
Laboratory measurements
The following laboratory parameters were assessed in all 
patients using standard methods: blood counts (haemoglo-
bin and platelets); renal function (creatinine and blood urea 
nitrogen); electrolytes (sodium and potassium); and plasma 
N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels 
(immunoenzymatic assay, Siemens, Marburg, Germany).
Haemodynamic assessment
An invasive assessment using a Swan-Ganz catheter was 
performed in patients referred for haemodynamic monitoring 
based on clinical evaluation. Indications for the procedure 
were as follows: 
 — clinical condition of patients with acute heart failure 
(AHF) — haemodynamic monitoring was a part of the 
standard cardiac intensive care in our institution;
 — chronic heart failure (CHF) — haemodynamic assessment 
in heart transplant or cardiac surgery candidates;
 — AHF/CHF patients — haemodynamic monitoring as a part 
of clinical trial procedures. If this was the case, all data 
used in this analysis were collected before randomisation 
or study intervention. 
Haemodynamic variables obtained during catheterisation 
included heart rate (HR), mean artery pressure (MAP), right 
atrial pressure (RAP), pulmonary artery pressure (PAP; systolic, 
diastolic, and mean), pulmonary capillary wedge pressure 
(PCWP), and cardiac output (CO; thermodilution method). 
Each invasive CO assessment included three to five separate 
injections of cold saline (10 mL) followed by CO calculation 
as a mean value of all injections. Cardiac index (CI) was de-
termined as CO divided by the body surface area. Systemic 
vascular resistance and pulmonary vascular resistance were 
calculated using standard formulas: 80 × (MAP – RAP)/CO 
and 80 × (PAP – PCWP)/CO, respectively. Systemic vascular 
resistance index and pulmonary vascular resistance index were 
computed by substituting CO with CI in the respective for-
mulas. Standard Swan-Ganz catheters (Edwards Lifesciences, 
Irvine, CA, USA) were used for monitoring.
Furthermore, blood samples from the right atrium and 
periphery were collected during the procedure for blood 
gas analysis, which included: pH, oxygen saturation (sO2) or 
mixed venous oxygen saturation (svO2; in the case of assess-
ment of right atrial blood samples), partial pressure of carbon 
dioxide (pCO2), bicarbonate, and lactate (direct method, 
ABL 800 Flex analyser, Radiometer, Copenhagen, Denmark).
Statistical analysis 
Continuous variables with normal distribution were described 
using means ± standard deviation; variables with skewed 
distribution were described by medians with upper and lower 
quartiles; categorised variables were given as numbers and 
percentages. Statistical significance of differences between the 
groups was assessed using t test and Mann-Whitney U test, 
where appropriate. The relationships between variables were 
assessed using Spearman rank coefficients. Multivariable 
regression analysis was performed to assess independent 
determinants of lactate. A p-value < 0.05 was considered 
statistically significant. Statistical analyses were performed 
using Statistica 12 (StatSoft Poland, Krakow, Poland).
RESULTS
Baseline characteristics
Baseline characteristics of the study population are presented 
in Table 1. The study comprised 93 patients, among whom 
44 (47%) had AHF and 49 (53%) had CHF. The participants 
were predominantly male (69 [74%]). The most relevant con-
comitant diseases were coronary artery disease in 41 (44%), 
hypertension in 30 (32%), diabetes mellitus in 21 (22%), 
and chronic obstructive pulmonary disease in eight (9%) 
patients. The most common concomitant medications used 
were diuretics (82 [88%]), angiotensin-converting enzyme 
inhibitor/angiotensin receptor blocker (70 [75%]), b-blockers 
(72 [77%]), and inotropes (14 [15%]). Mean age, systolic blood 
pressure, haemoglobin, and serum creatinine level on admis-
sion were 59 ± 13 years, 110 ± 19 mmHg, 13.2 ± 1.8 g/dL, 
and 1.1 ± 0.4 mg/dL, respectively. Mean lactate level and 
svO2 were 1.4 ± 0.9 mmol/L and 58% ± 12%, respectively. 
The median (upper and lower quartiles) plasma concentration 
of NT-proBNP was 4313 (2056; 7183) pg/mL.
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Table 1. Baseline characteristics and comparison of patients with acute and chronic heart failure







Heart failure aetiology: 0.005
Ischaemic 41 13 (32) 28 (68)
Valvular 37 28 (76) 9 (24)
Other 15 8 (53) 7 (47)
Age [years] 60 ± 13 57 ± 13 62 ± 12 0.06
HR [bpm] 75 ± 15 71 ± 12 79 ± 18 0.02
SBP [mmHg] 110 ± 18 113 ± 16 108 ± 22 0.24
LVEF [%] 33 ± 17 39 ± 19 26 ± 10 < 0.001







Sodium [mmol/L] 139 ± 4.2 139 ± 4.1 139 ± 4.5 0.6
Potassium [mmol/L] 4.2 ± 0.5 4.3 ± 0.51 4.0 ± 0.4 0.01
Creatinine [mg/dL] 1.15 ± 0.4 0.97 ± 0.2 1.3 ± 0.5 < 0.001
Bilirubin [µmol/L] 26.5 ± 16.2 22.2 ± 18.5 29.1 ± 11.8 0.12
AST [IU/L] 24 [19; 35] 25 [21; 37] 24 [18; 34] 0.37
ALT [IU/L] 23 [16; 36] 25 [18; 37] 20 [15; 34] 0.12
Glucose [mmol/L] 6.3 ± 1.9 5.9 ± 1.3 6.8 ± 2.3 0.053
HGB [g/dL] 13.2 ± 1.8 13.6 ± 1.5 12.7 ± 1.9 < 0.001
Lactate [mmol/L] 1.4 ± 0.9 1.1 ± 0.5 1.7 ± 1.1 < 0.001
sO2 [%] 91.6 ± 8.4 91 ± 9 91 ± 8 0.94
svO2 [%] 58.2 ± 12.0 64 ± 8 51 ± 12 < 0.001
Haemodynamic parameters:
CO [L/min] 4.1 ± 1.0 4.1 ± 0.92 4.0 ± 1.1 0.84
CI [L/min/m2] 2.2 ± 0.5 2.2 ± 0.3 2.2 ± 0.6 0.87
MAP [mmHg] 85 ± 14 88 ± 12 84 ± 16 0.11
PAP [mmHg] 36 ± 12 35 ± 10 37 ± 13 0.35
RAP [mmHg] 8.7 ± 6 7 ± 5 11 ± 6 0.001
PCWP [mmHg] 18 ± 6 17 ± 6 19 ± 6 0.19
SV [mL/beat] 55.7 ± 18 58 ± 17 54 ± 19 0.24
SVR [dyn/s/cm] 1578 ± 456 1652 ± 458 1492 ± 442 0.09
SVRI [dyn/s/cm] 2957 ± 729 3077 ± 649 2824 ± 795 0.09
PVR [dyn/s/cm] 368.7 ± 226 412 ± 271 319 ± 146 0.04
PVRI [dyn/s/cm] 695.4 ± 381 754 ± 450 629 ± 276 0.11
LVSWI [g/m2/beat] 28.1 ± 11 30 ± 9 26 ± 13 0.03
RVSWI [g/m2/beat] 11.1 ± 5 13 ± 5 9 ± 5 0.005
Data are presented as number (percentage), mean ± standard deviation, or median [lower and upper quartile]. AHF — acute heart failure;  
ALT — alanine aminotransferase; AST — aspartate aminotransferase; CHF — chronic heart failure; CI — cardiac index; CO — cardiac output;  
HGB — haemoglobin; HR — heart rate; LVEF — left ventricular ejection fraction; LVSWI — left ventricular stroke work index; MAP — mean artery 
pressure; NT-proBNP — N-terminal pro–B-type natriuretic peptide; PAP — pulmonary artery pressure; PCWP — pulmonary capillary wedge pres-
sure; PVR — pulmonary vascular resistance; PVRI — pulmonary vascular resistance index; RAP — right atrial pressure; RVSWI — right ventricular 
stroke work index; SBP — systolic blood pressure; sO2 — oxygen saturation; SV — stroke volume; svO2 — mixed venous oxygen saturation;  
SVR — systemic vascular resistance; SVRI — systemic vascular resistance index  
Conversion factors to SI units: for HGB — 10 g/L; for platelets — 1; for creatinine — 88.4 µmol/L; for NT-proBNP — 0.1182 pmol/L
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The mean CI, RAP, and PCWP in the study group were 
2.2 ± 0.5 L/min/m2, 9 ± 6 mmHg, and 18 ± 6 mmHg, 
respectively. 
Comparison of AHF and CHF patients
Patients with AHF had a significantly higher HR as well as 
NT-proBNP and creatinine levels compared to the CHF 
group (Table 1). Among haemodynamic indices, only el-
evated RAP differentiated AHF patients from those with 
CHF (11 ± 6 mmHg vs. 7 ± 5 mmHg, p < 0.05). Moreover, 
patients with AHF had significantly higher mean lactate levels 
(1.7 ± 1.1 mmol/L vs. 1.1 ± 0.5 mmol/L, p < 0.001) and 
lower svO2 (51% ± 12% vs. 64% ± 8%, p < 0.001) when 
compared to the CHF group (Table 1).
Correlates of lactate
Clinical, haemodynamic, and respiratory correlates of lactate 
are listed in Tables 2–4. Among clinical variables, only HR 
(r = 0.32, p < 0.05) and NT-proBNP (r = 0.28, p < 0.05) 
were significantly correlated with lactate. With regard to 
haemodynamic indices, lactate correlated with CI (r = –0.25, 
p = 0.01). We found no correlation between lactate and 
RAP, PCWP, or MAP (all p > 0.05). There was no relationship 
between lactate and peripheral blood gases pO2, pCO2, or 
sO2 (all p > 0.05). In contrast, lactate was strongly corre-
lated with pH and svO2 (r = –0.4, p < 0.05 and r = –0.61, 
p < 0.05, respectively; Fig. 1).
Determinants of lactate
Multivariable analysis revealed that the strongest predictors 
of lactate were HR (r = 0.92, p < 0.05), svO2 (r = –1.18, 
p < 0.05), and systemic vascular resistance (r = 0.52, 
p < 0.05) (Table 5).
DISCUSSION
For the first time, we showed that patients with AHF have 
a significantly higher lactate concentration than individuals 
in a stable, chronic state. This is not surprising because each 
AHF episode seems to be an energetic challenge for the 
body; however, to the best of our knowledge, it has not yet 
been clearly shown. The mean lactate concentration in the 
Figure 1. Correlation between lactate and mixed venous  
oxygen saturation (svO2)
Table 3. Haemodynamic correlates of lactate
Variables r p
CO [L/min] –0.20 0.055
CI [L/min/m2] –0.25 0.014
MAP [mmHg] –0.11 0.27
PAM [mmHg] –0.17 0.09
RAP [mmHg] –0.06 0.54
PCWP [mmHg] –0.05 0.66
SV [mL/beat] –0.32 0.002
SVR [dyn/s/cm] 0.12 0.24
SVRI [dyn/s/cm] 0.17 0.09
PVR [dyn/s/cm] –0.12 0.26
PVRI [dyn/s/cm] –0.11 0.29
LVSWI [g/m2/beat] –0.31 0.002
RVSWI [g/m2/beat] –0.29 0.004
Abbreviations — see Table 1
Table 2. Clinical and laboratory correlates of lactate
Variable r p
HR [bpm] 0.32 0.02
SBP [mmHg] 0.07 0.62
DBP [mmHg] –0.12 0.34
MAP [mmHg] –0.11 0.27
Creatinine [mg/dL] 0.13 0.31
BUN [mg/dL] –0.12 0.37
NT-proBNP [pg/mL] 0.28 0.03
HGB [g/dL] 0.07 0.54
WBC [G/L] 0.16 0.21
Platelets [G/L] –0.11 0.39 
BUN — blood urea nitrogen; DBP — diastolic blood pressure;  
WBC — white blood cells; other abbreviations — see Table 1
Table 4. Respiratory and metabolic correlates of lactate
Variable r p
pH –0.33 0.007
pO2 [mmHg] –0.14 0.26
pCO2 [mmHg] 0.18 0.14
HCO3
– [mmol/L] –0.16 0.21
sO2 [%] –0.01 0.97
svO2 [%] –0.61 < 0.0001
HCO3
– — bicarbonate; pCO2 — partial pressure of carbon dioxide;  
pO2 — partial pressure of oxygen; sO2 — oxygen saturation;  
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AHF group (~1.7 mmol/L) was not as high as we expected, 
and approximately one-third of patients had lactate levels 
above > 2 mmol/L. This is probably due to the fact that 
patients usually underwent Swan-Ganz catheterisation after 
initial treatment, which must have stabilised the patient and 
lowered the lactate level. However, this observation is in 
agreement with our previous report, in which we demon-
strated that approximately 40% of AHF patients (without 
clinical signs of hypoperfusion) had elevated (> 2 mmol/L) 
lactate levels on admission [7].
There are several potential pathways that lead to lac-
tate accumulation in AHF. We found moderate correlation 
of lactate with central haemodynamics. We also showed 
a relationship between lactate and CI and systemic vascular 
resistance. Of note, there were no correlations between 
lactate and markers of congestion (such as RAP and PCWP). 
It should also be highlighted that we found no relationship 
between systolic, diastolic, mean arterial pressure, and lactate 
levels. This observation is in agreement with our previous 
report; this is not unexpected because blood pressure is not 
a simple surrogate of CO [7]. For example, patients with high 
systolic blood pressure and high systemic vascular resistance 
(such as patients with pulmonary oedema) may have elevated 
lactate levels. The finding that lactate correlated with central 
haemodynamics (CI) is not surprising, but we need to remem-
ber that its production is probably a result of depravation 
of blood flow on the microvascular level (microcirculation), 
beyond the scope of this study.
Secondly, we showed that lactate is not related to pe-
ripheral blood saturation in HF. This observation is of key 
importance because it shows that lactate accumulation is 
not a result of hypoxaemia and insufficient oxygen delivery 
to tissues. Therefore, the imbalance between the supply and 
demand is instead a result of insufficient tissue perfusion and 
increased tissue oxygen demand rather than low oxygen supply. 
Most importantly, lactate is highly related to mixed venous 
oxygen saturation. The svO2 is a powerful marker reflecting 
tissue deoxygenation. Because it is measured in venous blood 
collected from the right atrium, it reveals the metabolic con-
sequences of tissue perfusion and CO. The svO2 is used in 
the Fick formula to estimate CO — the lower the svO2, the 
lower the CO. Generally, when microcirculatory blood flow 
is insufficient, the extraction of O2 increases, which leads 
to higher deoxygenation of the blood, and thus to lower 
svO2. The finding that the svO2 is the strongest, independent 
determinant of lactate is very important because it provides 
information not only about blood flow (perfusion) but also 
about its metabolic consequences.
Moreover, we revealed that lactate is strongly correlated 
with HR. This observation does not seem surprising because 
HR is associated with energy expenditure [9]. The relationship 
is obvious: the higher the HR, the higher the energy utilisa-
tion, which can lead to energy debt and lactate accumulation. 
This may also explain the fact that HR is a strong prognostic 
marker and a therapeutic goal in HF [8, 10, 11]. Although 
there are several known markers of HF severity and outcome, 
lactate and svO2 seem to be distinct because they reflect the 
metabolic consequences of the disease [11, 12].
Finally, we noted that the correlates/determinants of 
lactate in the CHF group were weaker than in the AHF group 
(data not shown). This observation may simply be a result of 
significantly lower mean values of lactates in CHF patients 
and — even more importantly — the lower dispersion of 
lactate in this group. 
We can conclude that lactate accumulation in HF is not 
a result of respiratory disturbances or hypoxaemia. Among 
haemodynamic indices, CI is correlated with lactate. However, 
the strongest determinants of lactate are mixed venous oxygen 
saturation (a unique metabolic marker of tissue metabolism), 
HR, and systemic vascular resistance. 
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WHAT IS NEW?
Lactate is an end-product of anaerobic cell metabolism, which is detectable in heart failure (HF) patients. Although lactate 
is believed to have prognostic significance in HF, data on the pathomechanisms that lead to its accumulation are scarce. 
Therefore, we attempted to analyse clinical, respiratory, biochemical, and haemodynamic determinants of lactate in HF 
patients who underwent haemodynamic monitoring with a Swan-Ganz catheter. We found that lactate accumulation 
in HF is not a result of respiratory disturbances. Among haemodynamic indices, cardiac index is correlated with lactate; 
no relationship was found between lactate and markers of congestion (such as right atrial pressure or pulmonary capil-
lary wedge pressure). For the first time, we have demonstrated that the strongest determinants of lactate include mixed 
venous oxygen saturation, systemic vascular resistance, and heart rate. This finding is in line with our understanding of 
hyperlactataemia pathophysiology in HF, because all these variables are markers of energy utilisation. 
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